← Back to Search

Behavioral Intervention

Penile Nerve Stimulation for Delayed Ejaculation

N/A
Waitlist Available
Led By Michael Eisenberg, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with delayed ejaculation
18 years or older
Must not have
Less than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a device that sends mild electrical pulses to the nerves in the penis to help men who have trouble ejaculating quickly enough. The goal is to see if this treatment can make ejaculation happen faster and improve overall sexual function.

Who is the study for?
This trial is for sexually active men aged 18 or older who have been diagnosed with delayed ejaculation. Participants must be capable of operating the device used in the study.
What is being tested?
The study tests if TENS, a method that uses electrical stimulation on penile nerves, can help reduce the time it takes for men with delayed ejaculation to reach climax during sexual activity.
What are the potential side effects?
Potential side effects may include discomfort at the site of stimulation, skin irritation from electrode pads, and possible temporary changes in sexual function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with delayed ejaculation.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean change from baseline in scores on International Index of Erectile Function
Secondary study objectives
Count of participants with treatment-related adverse events as assessed by survey

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TENS penile nerve stimulation groupExperimental Treatment1 Intervention
The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum). Participants will be able to use the device prior to sexual activity (immediately before sexual encounter for 10 minutes or daily for up to 14 days prior) to "prime" their system or during sexual activity. Each participant will use the device these three separate ways for 6 weeks each (total of 18 weeks of use).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TENS penile nerve stimulation
2019
N/A
~20

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcutaneous Electrical Nerve Stimulation (TENS) for Delayed Ejaculation (DE) involves applying electrical impulses to the penile nerves to modulate nerve activity. This method aims to enhance nerve signaling and improve the coordination of muscular contractions necessary for ejaculation. For DE patients, this non-invasive treatment directly targets the neural pathways involved in ejaculation, offering a potential solution without the need for systemic medications or invasive procedures.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,471 Previous Clinical Trials
17,501,762 Total Patients Enrolled
1 Trials studying Delayed Ejaculation
15 Patients Enrolled for Delayed Ejaculation
Michael Eisenberg, MDPrincipal InvestigatorStanford University
2 Previous Clinical Trials
19 Total Patients Enrolled
~2 spots leftby Nov 2025